Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

EAST HANOVER, N.J., July 8, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III trial results that showed more than one-third of patients taking Afinitor® (everolimus) tablets* experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC)(1,2,6). This study, the largest prospective clinical trial to date in this patient population, is being presented on Saturday, July 9 at the International TSC Research Conference in Washington, D.C.

Currently, Afinitor is approved in the US for the following indication: to treat patients with SEGA associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical intervention. The effectiveness of everolimus is based on an analysis of change in SEGA volume. Additionally, the indication states, clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown(7).

Tuberous sclerosis complex affects approximately 25,000 to 40,000 people in the US and one to two million people worldwide, and is associated with a variety of resulting disorders including seizures, swelling in the brain (hydrocephalus), developmental delays and skin lesions(2,6). Also known as tuberous sclerosis (TS), TSC is a genetic disorder that may cause non-cancerous tumors to form in vital organs and can affect many different parts of the body, most commonly the brain and kidney(6,8). Signs and symptoms of TSC vary depending on which system and which organs are involved(6). SEGAs occur in up to 20% of patients with TSC. In countries where everolimus is not approved, brain surgery is the only treatment option for patients with growing SEGAs(2).

The 117-patient, randomized, placebo-controlled Phase III EXIST-1 (EXamining everolimus In a Study of TSC) trial met its primary endpoin
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- Syneron Medical Ltd. (NASDAQ: ELOS ), a ... new PicoWay® device has received CE Mark indication to ... lesions on any skin type. PicoWay is a new ... wavelengths, which utilizes Syneron,s proprietary PicoWay technology to deliver ... of a second, known as picosecond pulses. Syneron will ...
(Date:7/28/2014)... July 28, 2014  ALPHAEON Corporation ... healthcare and subsidiary of Strathspey Crown ... Recommended Nutriceuticals (PRN) ® , a leading ... products for dry eye and macular ... transaction worth up to $55M. ...
(Date:7/28/2014)... , July 28, 2014 Concord Medical ... CCM ), a leading specialty hospital management ... radiotherapy and diagnostic imaging centers in China ... its Board of Directors declared a special cash dividend ... Depositary Share ("ADS")) on the Company,s outstanding ordinary shares. ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3Concord Medical Declares Special Dividend 2
... , WASHINGTON, Dec. 11 Nabe News ... medicines are in development to fight diabetes. The report details a ... clinical trials and awaiting approval by the U.S. Food and Drug Administration. ... ( PhRMA ). , Diabetics do not produce or properly use ...
... R.I., Dec. 11 CVS Caremark (NYSE: CVS ... Vice President and Chief Human Resources Officer, effective January 1, ... his retirement. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) , ... has more than 30 years of human resources experience. ...
Cached Medicine Technology:183 New Medicines in Development for Diabetes 2CVS Caremark Names New Chief Human Resources Officer 2
(Date:7/28/2014)... 28, 2014 A lush green lawn offers ... the summer. However, the summer heat, lack of rain, foot ... brown, weak and unhealthy. The Grounds Guys recommends these suggestions ... a lawn once a week and set the height on ... protects the grass roots from heat and allows roots to ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A January ... reduction of gluten intake in those who were self-diagnosed ... Mittry, director of nutrition for San Diego health and ... various gluten considerations for those who are unclear about ... explains that gluten is a protein, found in wheat, ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Quincy Bioscience, ... , is pleased to announce the release of the ... company president and co-founder Mark Underwood. , The Brain ... information, offering useful techniques for readers to improve memory ... an unavoidable conclusion, The Brain Health Guide provides ways ...
(Date:7/28/2014)... Dawn Echols’ professional background spans success in ... experience has honed her people skills and led ... counseling ( http://dawningphoenix.com ) work includes private practice, ... domestic violence. , As owner and executive ... individuals and groups for a variety of disorders. ...
(Date:7/28/2014)... -- Elementary school students seem to be satisfied with the ... new study of school officials. , , New meal standards ... into effect in the fall of 2012. At the time, ... throw away most of their food. But the new study ... case. , , "The updated meals standards are resulting in ...
Breaking Medicine News(10 mins):Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 3Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:Healthy School Lunches Get Thumbs Up From Students 2
... Infuser, a,medical device used extensively in Combat Support Hospitals to treat ... to,save the life of an Omaha, NE Police Officer. , ... during a traffic stop. One of the bullets,hit him in the ... "Injury to this area is ...
... don,t respond at first not helped by maintenance treatment, ... Maintenance therapy using low-dose peginterferon doesn,t help patients with ... initial round of treatment, new research suggests. , The ... with liver disease over the course of four years. ...
... can outperform animal and human derived serum in CHO cell culture. ... ... -- Cellastim has proven to be a robust replacement for serum ... kinetics and productivity of CHO cell lines across a variety of ...
... statement by Betsy Ryan, President and CEO, New Jersey Hospital ... today announced that six New Jersey hospitals will share funding ... news for those facilities, but the more sobering headline is ... away. While a worthy effort, clearly the needs of New ...
... Calif., Dec. 3 ThermoGenesis,Corp. (Nasdaq: KOOL ... process and store adult stem cells, said today that ... Board of Directors to resign as,the Chief Executive Officer ... board has named Matthew T. Plavan, the Company,s Executive,Vice ...
... Dec. 3 The makers of TYLENOL(r) Warming,Liquids have embarked ... so they can warm up. Already a success in New ... complimentary,transportation within the city limits. , ... the city limits of the,District of Columbia, with a maximum ...
Cached Medicine News:Health News:Belmont(R) Rapid Infuser Helps Save Officer's Life 2Health News:Hepatitis C Therapy Useless for Some 2Health News:InVitria's Cellastim Delivers Superior Results in CHO Cell Culture 2Health News:ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones 2Health News:ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones 3Health News:ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones 4Health News:ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones 5Health News:The Makers of TYLENOL(R) Warming Liquids Offer Free 'Warming' Taxi Rides in Washington, D.C. 2
Stryker Instruments, the leader in surgical helmets, offers its 4th generation of personal protection systems for todays surgical environment the Sterishield T4 System....
... The PROVISION Surgical Helmet System from ... and protection. This system helps meet OSHA ... body fluids, while creating a new standard ... addition to the PROVISION Helmet System from ...
...
... ground has a large surface ... For use with minicrocodile clip ... (1.75 in) long, 3.1 cm ... package contains 50 individually sealed ...
Medicine Products: